Hospital
Beverly Community Hospital Association
Beverly Community Hospital Association was paid $10.86M by Medicaid between Jan 2018 and Sep 2023, across 225 billing codes. Its largest line is 0450, Emergency room services — 19% of everything it billed.
33Billing provider infoBEVERLY COMMUNITY HOSPITAL ASSOCIATION
MONTEBELLO, CA 90640
MONTEBELLO, CA 90640
33aNPI1184628919assigned 06/09/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.86M
24GClaims653,167
24DCodes billed225
24AFirst – last monthJan 2018 – Sep 2023
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#172 of 410
Median peer was paid$6.90M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 119,700 | $1.74M | |
| 2019 | 103,349 | $1.58M | |
| 2020 | 77,306 | $1.14M | |
| 2021 | 98,015 | $1.71M | |
| 2022 | 141,614 | $2.55M | |
| 2023 | 113,183 | $2.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 19% | 53,985 | 47,520 | $2.05M |
| 70450 | Computed tomography, head or brain; without contrast material | 5.6% | 6,878 | 6,568 | $608K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.3% | 12,932 | 12,227 | $469K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.3% | 5,308 | 5,148 | $467K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.0% | 18,376 | 16,513 | $329K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.9% | 3,769 | 3,519 | $317K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.6% | 6,598 | 6,189 | $286K |
| 0120 | 2.6% | 120 | 106 | $278K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 1,653 | 1,609 | $258K |
| 99199 | Unlisted special service, procedure or report | 2.1% | 8,816 | 7,527 | $232K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.0% | 4,935 | 4,613 | $221K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.0% | 7,956 | 7,168 | $213K |
213 more codes
| Z7502 | 1.9% | 5,662 | $210K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 11,010 | $201K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 37,517 | $201K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.8% | 1,695 | $198K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 16,530 | $174K |
| 0762 | 1.6% | 3,278 | $174K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.5% | 1,071 | $160K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 23,832 | $137K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 5,120 | $136K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 2,384 | $126K |
| 99283 | Emergency room visit (moderate) | 1.0% | 2,137 | $113K |
| 83880 | <1% | 5,345 | $107K | |
| 80053 | Comprehensive metabolic panel | <1% | 14,130 | $102K |
| 84484 | <1% | 12,599 | $97K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,896 | $92K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,458 | $89K |
| 11043 | <1% | 2,979 | $88K | |
| 83690 | <1% | 15,931 | $83K | |
| 80076 | <1% | 13,434 | $81K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,716 | $80K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,851 | $76K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,692 | $76K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,513 | $74K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,380 | $73K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 486 | $70K |
| 0160 | <1% | 1,631 | $69K | |
| 0360 | <1% | 1,567 | $67K | |
| J3490 | Unclassified drugs | <1% | 24,583 | $63K |
| 76801 | <1% | 1,375 | $62K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,007 | $57K |
| 87040 | <1% | 5,776 | $57K | |
| 93971 | <1% | 727 | $52K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 278 | $51K |
| 0270 | <1% | 16,468 | $46K | |
| 81003 | <1% | 25,455 | $42K | |
| 99285 | Emergency room visit (most serious) | <1% | 204 | $41K |
| 93970 | <1% | 353 | $41K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,145 | $39K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,759 | $39K |
| 84703 | <1% | 8,572 | $38K | |
| 70496 | <1% | 258 | $38K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,624 | $35K |
| 0259 | <1% | 11,903 | $35K | |
| G0378 | Hospital observation service, per hour | <1% | 210 | $34K |
| 0301 | <1% | 1,328 | $33K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,278 | $33K |
| 99000 | <1% | 15,510 | $33K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,400 | $30K |
| 85730 | <1% | 6,758 | $30K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,242 | $29K |
| 0250 | <1% | 6,663 | $28K | |
| 73630 | <1% | 1,559 | $28K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,208 | $27K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,011 | $27K |
| 73610 | <1% | 1,412 | $26K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 288 | $26K |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | <1% | 934 | $25K |
| 90715 | <1% | 811 | $25K | |
| 85610 | <1% | 7,069 | $24K | |
| 87186 | <1% | 3,697 | $24K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,316 | $23K |
| 73130 | <1% | 1,163 | $23K | |
| 86140 | <1% | 6,259 | $22K | |
| 72100 | <1% | 1,003 | $22K | |
| 83605 | <1% | 2,910 | $21K | |
| 73030 | <1% | 1,109 | $21K | |
| 70498 | <1% | 206 | $21K | |
| 84702 | <1% | 2,128 | $19K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 318 | $19K |
| 87501 | <1% | 636 | $18K | |
| 85379 | <1% | 2,589 | $18K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 769 | $18K |
| 82947 | <1% | 5,556 | $18K | |
| 70486 | <1% | 176 | $17K | |
| 0710 | <1% | 1,190 | $17K | |
| 73562 | <1% | 845 | $16K | |
| 0252 | <1% | 5,835 | $16K | |
| 81025 | <1% | 3,851 | $15K | |
| 73110 | <1% | 687 | $15K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,416 | $14K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,180 | $13K |
| 0272 | <1% | 4,561 | $13K | |
| 80305 | <1% | 1,208 | $13K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,190 | $12K |
| 0278 | <1% | 32 | $11K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,564 | $11K |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,037 | $10K |
| 94664 | <1% | 1,306 | $10K | |
| Z7610 | <1% | 1,585 | $9K | |
| 73564 | <1% | 392 | $9K | |
| 82550 | <1% | 1,785 | $9K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 208 | $9K |
| A4217 | Sterile water/saline, 500 ml | <1% | 1,654 | $9K |
| 0510 | <1% | 432 | $9K | |
| Z7500 | <1% | 242 | $8K | |
| 73080 | <1% | 402 | $8K | |
| 0761 | <1% | 510 | $8K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,883 | $8K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,314 | $7K |
| 59899 | <1% | 1,450 | $7K | |
| 73590 | <1% | 410 | $7K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 313 | $7K |
| 0001A | <1% | 166 | $7K | |
| 83735 | <1% | 1,409 | $7K | |
| 97163 | <1% | 199 | $7K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,519 | $6K |
| 85027 | <1% | 1,443 | $6K | |
| 86900 | <1% | 2,936 | $6K | |
| 86901 | <1% | 2,368 | $5K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,402 | $5K |
| 86850 | <1% | 1,297 | $5K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,389 | $5K |
| 80061 | Lipid panel | <1% | 571 | $5K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,373 | $5K |
| 0257 | <1% | 2,389 | $5K | |
| 59425 | <1% | 159 | $5K | |
| 82553 | <1% | 553 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 916 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,321 | $4K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 719 | $4K |
| 73090 | <1% | 235 | $4K | |
| 84145 | <1% | 253 | $3K | |
| 74022 | <1% | 98 | $3K | |
| 85007 | <1% | 1,435 | $3K | |
| 82805 | <1% | 120 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 575 | $3K |
| 86738 | <1% | 279 | $3K | |
| 84100 | <1% | 838 | $3K | |
| 74018 | <1% | 199 | $3K | |
| 94729 | <1% | 94 | $3K | |
| 0271 | <1% | 1,899 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 419 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 518 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 627 | $2K |
| A4649 | Surgical supply; miscellaneous | <1% | 2,434 | $2K |
| 71020 | <1% | 106 | $2K | |
| 82150 | <1% | 365 | $2K | |
| 87634 | <1% | 50 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 858 | $2K |
| 87581 | <1% | 87 | $2K | |
| 90714 | <1% | 208 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 659 | $2K |
| 92611 | <1% | 63 | $2K | |
| 94726 | <1% | 83 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 233 | $2K |
| 0300 | <1% | 844 | $2K | |
| 87205 | <1% | 581 | $2K | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 24 | $2K |
| 82140 | <1% | 176 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 105 | $1K |
| 0002A | <1% | 31 | $1K | |
| 87420 | <1% | 359 | $1K | |
| 71250 | <1% | 13 | $1K | |
| 76870 | <1% | 24 | $940.49 | |
| 29125 | <1% | 106 | $897.80 | |
| 0750 | <1% | 13 | $815.20 | |
| 0305 | <1% | 621 | $762.15 | |
| 12001 | <1% | 16 | $759.81 | |
| 51701 | <1% | 31 | $742.85 | |
| 72131 | <1% | 12 | $696.47 | |
| 0258 | <1% | 568 | $669.82 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 116 | $664.83 |
| 76775 | <1% | 25 | $657.95 | |
| 99001 | <1% | 6,668 | $637.58 | |
| 73552 | <1% | 26 | $632.93 | |
| 72040 | <1% | 30 | $616.64 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 222 | $560.80 |
| 73060 | <1% | 28 | $507.72 | |
| 0636 | <1% | 275 | $507.34 | |
| 0324 | <1% | 192 | $434.98 | |
| 86592 | <1% | 83 | $402.93 | |
| 99070 | <1% | 565 | $364.19 | |
| 73140 | <1% | 26 | $340.85 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 33 | $300.27 |
| 96376 | <1% | 97 | $284.10 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 45 | $277.17 |
| 87071 | <1% | 13 | $274.66 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 20 | $256.38 |
| 96379 | <1% | 238 | $246.43 | |
| 87070 | <1% | 75 | $233.58 | |
| 72072 | <1% | 12 | $214.14 | |
| 94618 | <1% | 12 | $204.05 | |
| 0402 | <1% | 26 | $198.46 | |
| 0279 | <1% | 321 | $197.06 | |
| 85651 | <1% | 122 | $194.11 | |
| 97165 | <1% | 14 | $186.31 | |
| 0251 | <1% | 183 | $176.52 | |
| 86308 | <1% | 57 | $171.78 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 32 | $168.10 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 67 | $160.29 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 18 | $159.52 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 13 | $146.51 |
| 29515 | <1% | 25 | $140.55 | |
| 0320 | <1% | 14 | $122.28 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 24 | $122.27 |
| 29530 | <1% | 19 | $99.67 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 30 | $99.28 |
| J7070 | Infusion, d5w, 1000 cc | <1% | 15 | $79.30 |
| 82010 | <1% | 13 | $63.44 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 12 | $55.92 |
| 94760 | <1% | 23 | $54.28 | |
| 84479 | <1% | 12 | $41.88 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 20 | $35.81 |
| 0307 | <1% | 253 | $21.55 | |
| A4300 | Implantable access catheter, (e.g., venous, arterial, epidural subarachnoid, or peritoneal, etc.) external access | <1% | 12 | $7.55 |
| 0306 | 0% | 202 | $0.00 | |
| 0370 | 0% | 29 | $0.00 | |
| 0310 | 0% | 120 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 218 | $0.00 |
| 0730 | 0% | 149 | $0.00 | |
| 0483 | 0% | 13 | $0.00 | |
| 0302 | 0% | 255 | $0.00 | |
| 0424 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMATHEW, JAMES (SR. DIRECTOR)